Inhibitors against the production and release of inflammatory cytokines

1. A method for therapeutic treatment of a disease caused by NF-κB activation in a mammal with the disease, which comprises administering to the mammal a therapeutically effective amount of a compound selected from the following:

N-[3,5-Bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide,

N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-5-nitrobenzamide,

N-[3,5-Bis(trifluoromethyl)phenyl]-4-hydroxybiphenyl-3-carboxamide,

N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-5-(trifluoromethyl)-benzamide,

N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-5-(pyrrol-1-yl)benzamide,

N-[2,5-Bis(trifluoromethyl)phenyl]-5-bromo-2-hydroxybenzamide,

5-Bromo-N-[3-bromo-5-(trifluoromethyl)phenyl]-2-hydroxybenzamide,

5-Bromo-N-[2-chloro-5-(trifluoromethyl)phenyl]-2-hydroxybenzamide,

5-Chloro-2-hydroxy-N-[2-methyl-5-(trifluoromethyl)phenyl]benzamide, and

2-Hydroxy-5-methyl-N-[2-methyl-5-(trifluoromethyl)phenyl]benzamide;

or a pharmacologically acceptable salt thereof, wherein the disease is chronic rheumatism, osteoarthritis, systemic lupus erythematosus, systemic scleroderma, polymyositis, Sjoegren's syndrome, vasculitis syndrome, antiphospholipid antibody syndrome, Still's disease, Behcet's disease, periarteritis nodosa, ulcerative colitis, Crohn's disease, active chronic hepatitis, glomerulonephritis, chronic pancreatitis, gout, atherosclerosis, multiple sclerosis, arteriosclerosis, intimal hypertrophy, psoriatic arthritis, contact dermatitis, atopic dermatitis, pollinosis, asthma, bronchitis, interstitial pneumonia, chronic obstructive lung disease, chronic pulmonary thromboembolism, inflammatory colitis, insulin resistance, obesity, diabetes, nephropathy, retinopathy, neurosis, hyperinsulinemia, hypertension, peripheral vessel obstruction, hyperlipemia, Alzheimer's disease, acute hepatitis, chronic hepatitis, drug induced toxic hepatopathy, alcoholic hepatitis, viral hepatitis, cirrhosis, hepatic insufficiency, atrial myxoma, Castleman's syndrome, mesangial nephritis, solid cancer, sarcoma, osteosarcoma, metastatic invasion of cancer, canceration of inflammatory focus, cancerous cachexia, metastasis of cancer, leukemia, multiple myeloma, Lennert's lymphoma, malignant lymphoma, development of carcinostatic resistance of cancer, brain tumor, nervous tumor, cytomegaloviral pneumonia, cytomegaloviral retinopathy, adenoviral cold, adenoviral pool fever, adenoviral ophthalmia, AIDS, restenosis after percutaneous transluminal coronary angioplasty, ischemia reperfusion disorders, organ transplantation rejection and reperfusion disorders, chronic fatigue syndrome, osteoporosis, or bone cancer pain.

2. The method according to claim 1 , wherein the mammal is a human.

3. The method according to claim 1 , wherein the compound is N-[3,5-Bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide.

4. The method according to claim 1 , wherein the compound is N-[2,5-Bis(trifluoromethyl)phenyl]-5-bromo-2-hydroxybenzamide.

5. The method according to claim 1 , wherein the disease is chronic rheumatism or osteoarthritis.

6. The method according to claim 1 , wherein the disease is insulin resistance, obesity, diabetes, nephropathy, retinopathy, neurosis, hyperinsulinemia, hypertension, or peripheral vessel obstruction.

7. The method according to claim 1 , wherein the disease is Alzheimer's disease.

8. The method according to claim 1 , wherein the disease is solid cancer, sarcoma, osteosarcoma, metastatic invasion of cancer, cancerous cachexia, metastasis of cancer, leukemia, multiple myeloma, Lennert's lymphoma, malignant lymphoma, development of carcinostatic resistance of cancer, brain tumor, or nervous tumor.

9. The method according to claim 1 , wherein the disease is solid cancer.

10. The method according to claim 1 , wherein the disease is contact dermatitis or atopic dermatitis.